Javascript must be enabled to continue!
Correlation of Human Epidermal Growth Factor Receptor (Her2-neu) Marker with the Grades of Urothelial Carcinoma
View through CrossRef
Background: Urothelial carcinoma is the common carcinoma of urothelium. Its incidence is high in developed countries but itsoccurrence is increasing in developing countries like Pakistan with mortality rate of 3.8/100,000 in males and 1/100,000 in females.HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family.Amplification or over-expression ofthis oncogene has been shown to play an important role in the development and progression urothelial carcinoma.Objective: To evaluate the relationship between HER2/NEU expression and grades of urothelial carcinoma bladderMaterial and Methods: This was a cross-sectional descriptive study for the period of six months from January to June, 2017conducted at Pathology section Rehman Medical Institute Peshawar. After approval from university Ethical board 63 cases wereselected by purposive sampling.The Tissue samples from diagnosed cases of urothelial carcinoma of urinary bladder were included.Cases of urothelial carcinoma from other sites were excluded. Paraffin embedded tissue blocks were cut and sections stained byH&E to evaluate histopathological features and tumor grades. Immunohistochemical expression of HER2 was determinedapplying standard techniques of immunohistochemistry.Results: Out of total 63 cases, 47 were males and 16 were female with a mean age of 60.7 years (range 14-90 years). There were38 High grade, 23 Low grade and 2 cases of PUNLMP. 36 cases were positive for HER2 expression in which 26(72.2%) were Highgrade, 9(25%) of Low grade and 1(2.7%) of PUNLMP. High grade was more common in HER2 positive cases and this relationshipwas significant (p<.05). Among positive 36 cases, 19 cases of +3 score were High grade, 05 in Low grade and 01 in PUNLMP whilescore 2+ was in 07 cases of High grade and 04 were in Low grade. The relationship of HER2 score was not significantly related tograde of tumor (p>.05)Conclusion: HER2 is highly expressed in high grades of urothelial carcinoma bladder and this relationship between HER2expression and tumor grades is statistically significant.Keywords: HER2, Urothelial carcinoma, Grades, Immunohistochemistry
Title: Correlation of Human Epidermal Growth Factor Receptor (Her2-neu) Marker with the Grades of Urothelial Carcinoma
Description:
Background: Urothelial carcinoma is the common carcinoma of urothelium.
Its incidence is high in developed countries but itsoccurrence is increasing in developing countries like Pakistan with mortality rate of 3.
8/100,000 in males and 1/100,000 in females.
HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family.
Amplification or over-expression ofthis oncogene has been shown to play an important role in the development and progression urothelial carcinoma.
Objective: To evaluate the relationship between HER2/NEU expression and grades of urothelial carcinoma bladderMaterial and Methods: This was a cross-sectional descriptive study for the period of six months from January to June, 2017conducted at Pathology section Rehman Medical Institute Peshawar.
After approval from university Ethical board 63 cases wereselected by purposive sampling.
The Tissue samples from diagnosed cases of urothelial carcinoma of urinary bladder were included.
Cases of urothelial carcinoma from other sites were excluded.
Paraffin embedded tissue blocks were cut and sections stained byH&E to evaluate histopathological features and tumor grades.
Immunohistochemical expression of HER2 was determinedapplying standard techniques of immunohistochemistry.
Results: Out of total 63 cases, 47 were males and 16 were female with a mean age of 60.
7 years (range 14-90 years).
There were38 High grade, 23 Low grade and 2 cases of PUNLMP.
36 cases were positive for HER2 expression in which 26(72.
2%) were Highgrade, 9(25%) of Low grade and 1(2.
7%) of PUNLMP.
High grade was more common in HER2 positive cases and this relationshipwas significant (p<.
05).
Among positive 36 cases, 19 cases of +3 score were High grade, 05 in Low grade and 01 in PUNLMP whilescore 2+ was in 07 cases of High grade and 04 were in Low grade.
The relationship of HER2 score was not significantly related tograde of tumor (p>.
05)Conclusion: HER2 is highly expressed in high grades of urothelial carcinoma bladder and this relationship between HER2expression and tumor grades is statistically significant.
Keywords: HER2, Urothelial carcinoma, Grades, Immunohistochemistry.
Related Results
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome
HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome
Abstract
Aims
Apocrine carcinoma of the breast (APO) expresses HER2 in 30-50% of cases. This study explored the clinicopathological features and outcome of HER2+ APO (HER2...
Abstract 2271: bcl-2 expression in HER2-positive breast carcinoma subtypes
Abstract 2271: bcl-2 expression in HER2-positive breast carcinoma subtypes
Abstract
Background: HER2-positive breast cancers comprise 20-30% of all breast cancers; amplification of HER2 confers a poorer prognosis. While treatment with anti-...
Abstract BL-1: Brinker Award Lecture: How Does HER2 Contribute to Breast Cancer Progression?
Abstract BL-1: Brinker Award Lecture: How Does HER2 Contribute to Breast Cancer Progression?
Abstract
HER2 (also called NEU and ERBB2), a receptor tyrosine kinase frequently overexpressed in breast cancer, is one of the most oncogenic kinases of the human ki...
Abstract 1836: Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition
Abstract 1836: Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition
Abstract
Background While HER2-directed agents are most often used for treating breast cancer, there is increasing evidence that these therapies may be of value in o...
Functional analysis of a putative HER2-associated expressed enhancer, Her2-Enhancer1, in breast cancer cells
Functional analysis of a putative HER2-associated expressed enhancer, Her2-Enhancer1, in breast cancer cells
AbstractHER-2/neu (HER2) is a member of the epidermal growth factor receptors family, encoding a protein with tyrosine kinase activity. Following the gene amplification or increase...
Functional analysis of a putative HER2-associated expressed enhancer, Her2- Enhancer1, in breast cancer cells
Functional analysis of a putative HER2-associated expressed enhancer, Her2- Enhancer1, in breast cancer cells
Abstract
HER-2/neu (HER2) is a member of epidermal growth factor receptors (EGFR) family, encoding a protein with tyrosine kinase activity. Following the gene amplification...
Abstract PS4-31: Characteristics of HER2/neu positive breast cancer among patients with and without germline BRCAmutations
Abstract PS4-31: Characteristics of HER2/neu positive breast cancer among patients with and without germline BRCAmutations
Abstract
Introduction: Breast cancer in BRCA 1/2 carriers is a well-characterized disease process, and its association with triple negative breast cancer has been ex...


